I4T-MC-JVCY: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514269-20-00

Acronym

I4T-MC-JVCY

Enrollment

Registered

2024-08-21

Start date

2015-05-06

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Non-Small Cell Lung Cancer

Brief summary

Part B (Placebo + Erlotinib): Progression Free Survival (PFS) [ Time Frame: Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months) ], Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: Cycle 1 Day 1 through End of Study (Up To 3 Years) ]

Interventions

DRUGRAMUCIRUMAB

DRUGERLOTINIB

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Part B (Placebo + Erlotinib): Progression Free Survival (PFS) [ Time Frame: Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months) ], Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: Cycle 1 Day 1 through End of Study (Up To 3 Years) ]	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026